Effect of sample heat inactivation on test levels of HIT-IgG (PF4-H) detected by the ACL AcuStar

Emmanuel J. Favaloro, Soma Mohammed, Dea Donikian, Mayuko Kondo, Sayed Hamdam, Naomi Hocker, Timothy Brighton

Research output: Contribution to journalLetterpeer-review


Heparin induced thrombocytopenia (HIT) characterises a significant complication of heparin therapy, whilst heparin in turn reflects a common anticoagulant, especially in hospital settings. Some patients develop antibodies that cause platelet activation, thrombin generation, and subsequently thrombosis (arterial, venous and/or microvascular) and related morbidity (‘pathological HIT’). The ACL AcuStar represents an emerging technology in the haemostasis field, and HIT testing (HIT-IgG (PF4-H) assay) is available. We recently reported our experience with this assay, identifying this as an excellent screen for pathological HIT antibodies (i.e., high association with a gold-standard functional assay, namely serotonin release assay; SRA).
Original languageEnglish
Pages (from-to)12-15
Number of pages4
JournalThrombosis Research
Early online date17 Jan 2021
Publication statusPublished - 01 Apr 2021


Dive into the research topics of 'Effect of sample heat inactivation on test levels of HIT-IgG <sub>(PF4-H)</sub> detected by the ACL AcuStar'. Together they form a unique fingerprint.

Cite this